THEODORE J. ABERNETHY, M.D.; HARRY F. DOWLING, M.D.; CLARENCE R. HARTMAN, M.D.
Since the demonstration by Whitby1 of the specific action of sulfapyridine against the pneumococcus, the value of this new chemotherapeutic agent in the treatment of lobar pneumonia has been the subject of extensive clinical investigation. The report of Evans and Gaisford,2 describing the results of treatment of 100 patients ill with lobar pneumonia, was so impressive that a stimulus was given for a wide-spread trial of the drug in this country. Subsequent publications,3-7 already voluminous, not only have confirmed the observations of Evans and Gaisford, but have established a definite place for sulfapyridine in the treatment of pneumococcus lobar pneumonia.
ABERNETHY TJ, DOWLING HF, HARTMAN CR. THE TREATMENT OF LOBAR PNEUMONIA WITH SULFAPYRIDINE AND SODIUM SULFAPYRIDINE, WITH OBSERVATIONS UPON EFFECTIVE BLOOD LEVELS(THE TREATMENT OF LOBAR PNEUMONIA WITH SULFAPYRIDINE AND SODIUM SULFAPYRIDINE, WITH OBSERVATIONS UPON EFFECTIVE BLOOD LEVELS*). Ann Intern Med. 1940;13:1121–1137. doi: 10.7326/0003-4819-13-7-1121
Download citation file:
Published: Ann Intern Med. 1940;13(7):1121-1137.
Infectious Disease, Pneumonia, Pulmonary/Critical Care.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use